Prelude Capital Management, LLC Cytom X Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $10,999 - $13,430	-1,700 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $8,515 - $11,479	1,300 Added 325.0%	1,700 $11,000
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $2,960 - $5,856	400 New	400 $3,000
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $4,509 - $7,484	-611 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $5,712 - $6,971	611 New	611 $7,000
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $913 - $1,339	-72 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $187,345 - $274,267	-10,385 Reduced 99.31%	72 $1,000
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $197,850 - $274,658	9,254 Added 769.24%	10,457 $239,000
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $17,451 - $27,444	802 Added 200.0%	1,203 $34,000
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $7,619 - $9,259	401	401 $8,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.